"Our lead product, SAR-bisPSMA continues to generate exceptional data in diagnostic and theranostic trials as well as under the Expanded Access Programs (EAP), and we are fully committed to bringing it to prostate cancer patients in need of improved diagnostic and treatment options. We look forward to sharing some news on the progress of our SECuRE theranostic trial shortly as it is progressing through the highest dose level cohort of the trial with up to 4 doses of 67Cu-SAR-bisPSMA."
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.39 |
Change
0.300(14.4%) |
Mkt cap ! $768.3M | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.40 | $2.07 | $8.519M | 3.760M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 4380 | 2 |
View Market Depth
| Last trade - 16.21pm 26/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |